Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT01543204
- Locations
- 🇨🇦
Research Site, Waterloo, Ontario, Canada
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 109
- Registration Number
- NCT01421069
- Locations
- 🇳🇴
Depart. of Rheumatology, Oslo, Norway
🇸🇮University Medical Centre Ljubljana, University Children's Hospital, Ljubljana, Slovenia
🇮🇹Centro di Ricerca Clinica - Fondazione dell'Universita' degli Studi "G. D'Annunzio", Chieti Scalo, Italy
Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01372930
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1306
- Registration Number
- NCT01358578
- Locations
- 🇬🇧
Novartis Investigative Site, Nuneaton, United Kingdom
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3080
- Registration Number
- NCT01331837
- Locations
- 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸Apex Medical Research, AMR, Inc., Chicago, Illinois, United States
🇺🇸Columbus Arthritis Center, Columbus, Ohio, United States
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 210
- Registration Number
- NCT01313208
- Locations
- 🇨🇦
Research Site, Quebec, Canada
A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT01298531
- Locations
- 🇫🇷
Institut Calot - Fondation Hopale, Berck-sur-Mer, France
🇫🇷Hopital Pellegrin, Bordeaux Cedex, France
🇫🇷Centre Hospitalier, Service de Rhumatologie, Cahors, France
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Julia Brown
- Target Recruit Count
- 122
- Registration Number
- NCT01295151
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Effects of Denosumab on the Pharmacokinetics of Etanercept
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT01294397
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Etanercept (Enbrel) in Undifferentiated Spondyloarthritis
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 8
- Registration Number
- NCT01289730
- Locations
- 🇩🇪
Charite Campus Benjamin Franklin, Rheumatology, Berlin, Germany
🇩🇪Rheumazentrum Ruhrgebiet, Herne, Nordrhrein-Westfalen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.